Light‐activated carbon monoxide prodrugs based on bipyridyl dicarbonyl ruthenium(II) complexes

0532238 - ÚMCH 2021 RIV DE eng J - Článek v odborném periodiku
Geri, S. - Krunclová, Tereza - Janoušková, Olga - Pánek, Jiří - Hrubý, Martin - Hernández-Valdés, D. - Probst, B. - Alberto, R. A. - Mamat, C. - Kubeil, M. - Stephan, H.
Light‐activated carbon monoxide prodrugs based on bipyridyl dicarbonyl ruthenium(II) complexes.
Chemistry - A European Journal. Roč. 26, č. 48, SI (2020), s. 10992-11006. ISSN 0947-6539. E-ISSN 1521-3765
Grant CEP: GA ČR(CZ) GA19-01438S
Grant ostatní: AV ČR(CZ) DAAD-19-09
Program: Bilaterální spolupráce
Institucionální podpora: RVO:61389013
Klíčová slova: carbon monoxide * prodrug * light activation
Obor OECD: Polymer science
Impakt faktor: 5.236, rok: 2020
Způsob publikování: Open access
https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/chem.202002139

Two photoactivatable dicarbonyl ruthenium(II) complexes based on an amide‐functionalised bipyridine scaffold (4‐position) equipped with an alkyne functionality or a green‐fluorescent BODIPY (boron‐dipyrromethene) dye have been prepared and used to investigate their light‐induced decarbonylation. UV/Vis, FTIR and 13C NMR spectroscopies as well as gas chromatography and multivariate curve resolution alternating least‐squares analysis (MCR‐ALS) were used to elucidate the mechanism of the decarbonylation process. Release of the first CO molecule occurs very quickly, while release of the second CO molecule proceeds more slowly. In vitro studies using two cell lines A431 (human squamous carcinoma) and HEK293 (human embryonic kidney cells) have been carried out in order to characterise the anti‐proliferative and anti‐apoptotic activities. The BODIPY‐labelled compound allows for monitoring the cellular uptake, showing fast internalisation kinetics and accumulation at the endoplasmic reticulum and mitochondria.
Trvalý link: http://hdl.handle.net/11104/0310928